Hospital

Jim Schwartz, RPh, executive director of pharmacy operations for Oncology Pharmacy Services, discusses his presentation at the Community Oncology Alliance 2022 conference on the new world of oral cancer drug dispensing.

In an interview with Pharmacy Times®, Eric Tichy, PharmD, MBA, BCPS, FAST, FCCP, Vice Chair of Pharmacy/Formulary at Mayo Clinic, discusses some formulary trends in biosimilars at the Academy of Managed Care Pharmacy Annual Meeting.

Additional support is necessary to ensure that infrastructure development continues and that all pharmacists have the necessary tools to continue to provide immunization services.

A recent meta-analysis of statins showed that prevalence of statin intolerance is less than 10%, according to the panel.

Drug meets primary endpoint at 50 mg with reduction in low-density lipoprotein levels from the baseline in the ETESIAN phase 2b trial

Alpelisib is the first FDA-approved treatment for PROS, which is a range of rare conditions characterized by overgrowths and blood vessel anomalies.

Roche’s Actemra/RoActemra is aimed at patients receiving systemic corticosteroids who require extracorporeal membrane oxygenation, mechanical ventilation, or supplemental oxygen.

Evidence indicates that low-dose tramadol is a generally safe, effective, and fast-acting antidepressant for a substantial number of individuals suffering from depression.

Pharmacy workflow changes in the preparation of chemotherapy products can reduce patient chair time.

The entire pharmacy profession and all those interested in medication safety need to coalesce around the need for systemic change in community pharmacy workplace environments.

Lipitor is an inhibitor of HMG-CoA reductase indicated as an adjunct therapy to diet to treat high cholesterol and triglyceride levels.

Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being evaluated for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

Session at American College of Cardiology Scientific Sessions 2022 highlight treatments for symptomatic obstructive hypertrophic cardiomyopathy.

Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.

Multiple approaches can be taken to optimize medical therapy in patients with PAD.

Despite the approval of exciting new therapies for heart failure, there are still some challenges that need to be addressed to improve patient outcomes.

Common issues that affect patient outcomes include economic stability, education access, health care access, social and community context, and neighborhood environment.

Results of the phase 3 VOYAGER PAD clinical trial show rivaroxaban (Xarelto; Janssen Pharmaceutical Companies) plus aspirin lowers severe vascular events in patients with peripheral arterial disease after lower-extremity revascularization.

Empagliflozin (Jardiance, Boehringer Ingelheim/Lilly) tablets are the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death.

Session explores data from both the SCORED trial of sotagliflozin and the REVERSE-IT trial investigating bentracimab to reverse the antiplatelet effects of ticagrelor.

Health care professionals need to meet their patients at their health level and find a diet and medication regimen that works for them to best reduce the risk of cardiovascular events.

Lowering salt intake was not found to reduce visits to the emergency department, however, there were improvements in quality of life.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the barriers that patients with cancer may encounter following their diagnosis.

Session at the Hematology/Oncology Pharmacy Association Annual Conference 2022 focuses on methods to improve emotional exhaustion among pharmacists and other health care providers.

Rucaparib (Rubraca) significantly improved progression-free survival when administered as maintenance treatment in newly diagnosed patients with advanced ovarian cancer.

Ted Okon, MBA, executive director of the Community Oncology Alliance (COA), discusses key highlights from the in-person COA 2022 conference.

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

Pharmacist interactions provide significant benefits for patients with non-small cell lung cancer treated with oral oncolytics.